Abstract
Eleven men with major depression and human immunodeficiency virus (HIV) infection underwent an open trial of imipramine. Eight of nine (89%) who completed 12 weeks responded. The mean decline in T4 cells from baseline was 100 at week 12 and 16 at week 26. No major exacerbations of HIV infection occurred.